Browsing Centre for Cancer Biomarkers & Biotherapeutics by Issue Date
Now showing items 1-12 of 12
-
Field cancerization in breast cancer
(2022) -
Ferroptosis-Related Genes Are Potential Therapeutic Targets and the Model of These Genes Influences Overall Survival of NSCLC Patients
(MDPI, 2022-07-15)Background: Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSCC) are two of the most common subtypes of non-small cell lung cancer (NSCLC), with high mortality rates and rising incidence worldwide. Ferroptosis ... -
Non-Invasive Biomarkers for Early Lung Cancer Detection
(MDPI, 2022-11-24)Worldwide, lung cancer (LC) is the most common cause of cancer death, and any delay in the detection of new and relapsed disease serves as a major factor for a significant proportion of LC morbidity and mortality. Though ... -
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma
(Springer, 2023-04-03)Background Pegylated arginine deiminase (ADI-PEG20; pegargiminase) depletes arginine and improves survival outcomes for patients with argininosuccinate synthetase 1 (ASS1)-deficient malignant pleural mesothelioma (MPM). ... -
Circulating tumour cells for early detection of clinically relevant cancer
(Nature Research, 2023-06-02)Given that cancer mortality is usually a result of late diagnosis, efforts in the field of early detection are paramount to reducing cancer-related deaths and improving patient outcomes. Increasing evidence indicates that ... -
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
(Nature Research, 2023-11-09)The transferability and clinical value of genetic risk scores (GRSs) across populations remain limited due to an imbalance in genetic studies across ancestrally diverse populations. Here we conducted a multi-ancestry ... -
Molecular characteristics of early-onset pancreatic ductal adenocarcinoma.
(2023-12-25)The median age of patients with pancreatic ductal adenocarcinoma (PDAC) at diagnosis is 71 years; however, around 10% present with early-onset pancreatic cancer (EOPC), i.e., before age 50. The molecular mechanisms underlying ... -
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
(American Medical Association, 2024-02-15)IMPORTANCE: Arginine deprivation using ADI-PEG20 (pegargiminase) combined with chemotherapy is untested in a randomized study among patients with cancer. ATOMIC-Meso (ADI-PEG20 Targeting of Malignancies Induces ... -
Analysis of urinary potassium isotopes and association with pancreatic health: healthy, diabetic and cancerous states
(Frontiers Media, 2024-04-02)Background: More than 700 million people worldwide suffer from diseases of the pancreas, such as diabetes, pancreatitis and pancreatic cancer. Often dysregulation of potassium (K+) channels, co-transporters and pumps can ... -
Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.
(American Society of Clinical Oncology (ASCO), 2024-05-29)